Welcome to Therawis

Our mission is to combine highly innovative and novel diagnostics with effective therapeutics in oncology:

”The theranostic approach”

therascreen PITX2 RGQ PCR Kit (QIAGEN) is a novel clinically validated CE-IVD assay to determine the level of PITX2 methylation which helps predicting patient outcome to anthracycline-based chemotherapy and may help improve therapy decision-making.

Contact:

Therawis Pharma GmbH

Therawis Diagnostics GmbH

Grillparzerstrasse 14

81675 Munich Germany

Tel.: +49 (0) 89 41 42 45 57 0

Fax. +49 (0) 89 41 42 45 57 40

E-Mail: info@therawis.com

Website: http://www.therawis.com

 

Where to meet us:

< 2018 >
February
  • 21

    All day
    2018.02.21

    United Scientific Group is hosting International Conference on Biomarker Research in Clinical Medicine, scheduled for February 19-21, 2018 in beautiful and dazzling city of Paris, France. BRCM-2018 will uncover different facets of Biomarker study from research to therapy and its applications in divergent fields of Clinical Sciences.

    Presenter: Prof. Wilhelm

  • 22

    13:00 -14:00
    2018.02.22Europe/Berlin

    A clinical view on PITX2 DNA methylation in high-risk breast cancer

    Thursday, Feb. 22, 2018 at 1:00 p.m. CET

    Presenter: Prof. Wilhelm

© 2018 Therawis - All Rights Reserved